Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide Combination Therapy for Chronic Hepatitis C Genotype 4
NCT00421434Phase 3Completed
- Sponsor
- Romark Laboratories
- Start
- Jun 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nitazoxanide in hepatitis C (HCV) (3 arms), sponsored by Romark Laboratories. Primary endpoint: Sustained Virologic Response. Started Jun 2006; status: completed.
02
Drugs
nitazoxanide
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00421434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421434.